NCT04837196View on ClinicalTrials.gov

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions

Advanced MalignanciesAdvanced Cancer

Interventions

DRUG

ASP7517

Intravenous (IV)

DRUG

Pembrolizumab

Intravenous (IV)

Trial Locations (4)

15232

UPCI Hillman Cancer Center, Pittsburgh

30322

Emory University, Atlanta

52242

University of Iowa Hospitals, Iowa City

60603

University of Chicago, Chicago

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04837196 - Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Biotech Hunter | Biotech Hunter